This article is more than 5 years old. Information may no longer be current.

FDA approves Perrigo generic equivalents for dermatitis treatment

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The FDA has given final approval for Perrigo Co.’s abbreviated new drug applications for fluocinolone acetonide scalp oil, 0.01%, and fluocinolone acetonide topical oil, 0.01%, the company announced.

The products are the generic equivalent of Derma-Smoothe/FS Scalp Oil and Derma-Smoothe/FS Body Oil (Hill Dermaceuticals) and are indicated for topical treatment of atopic dermatitis in adults and topical treatment of moderate to severe atopic dermatitis in pediatric patients aged 3 months and older for up to 4 weeks, according to a press release. Perrigo anticipates shipping the products in September.

“This is another example of our Rx team’s commitment to launching difficult-to-manufacture topicals, lotions and foams,” Joseph C. Papa, Perrigo chairman and chief executive office, said in the release.